Robuta

https://pubmed.ncbi.nlm.nih.gov/24982505/ High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis Langerhans cell histiocytosis (LCH) represents a clonal proliferation of Langerhans cells. BRAF V600E mutations have been identified in approximately 50% of... https://pubchem.ncbi.nlm.nih.gov/bioassay/1793982 AID 1793982 - KinomeScan assay: inhibition of BRAF(V600E) - PubChem BioAssay record AID 1793982 submitted by ChEMBL: KinomeScan assay: inhibition of BRAF(V600E). aidassayinhibitionbrafpubchem https://pubmed.ncbi.nlm.nih.gov/35026411/ Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated... These updated results confirm the substantial clinical benefit and manageable toxicity of dabrafenib plus trametinib in BRAF V600E-mutant ATC. Dabrafenib plus... https://pubchem.ncbi.nlm.nih.gov/bioassay/1746919 AID 1746919 - Induction of apoptosis in human A375 cells expressing wild-type NRAS and BRAF V600E... BioAssay record AID 1746919 submitted by ChEMBL: Induction of apoptosis in human A375 cells expressing wild-type NRAS and BRAF V600E mutant at 1-3 uM relative... https://pmc.ncbi.nlm.nih.gov/articles/PMC9660367/ Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in... Thymosin beta-4 (TMSB4X) was recently identified as a differentially expressed gene between malignant and non-malignant thyroid cells via single-cell RNA... https://pubmed.ncbi.nlm.nih.gov/16024606/ Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers The BRAF V600E mutation has been associated with microsatellite instability and the CpG island methylator phenotype (CIMP) in colon cancer. We evaluated a... https://pubchem.ncbi.nlm.nih.gov/bioassay/1799024 AID 1799024 - B-RAF (V600E) Kinase Inhibition Assay from Article 10.1021/jm801509w:... BioAssay record AID 1799024 submitted by BindingDB: B-RAF (V600E) Kinase Inhibition Assay from Article 10.1021/jm801509w: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1608538/full Frontiers | Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic... BackgroundBRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited response to standard therapies. Recent clinical... https://pmc.ncbi.nlm.nih.gov/articles/PMC9563418/ TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience... TERT promoter mutation has recently emerged as a promising prognostic biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation.... https://pmc.ncbi.nlm.nih.gov/articles/PMC9338780/ Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated... Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on... https://iris.cnr.it/handle/20.500.14243/369244 BRAF(V600E)-mutant cancers display a variety of networks by SWIM analysis: prediction of... https://pubmed.ncbi.nlm.nih.gov/26823846/ Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in... The V600E mutation in the B-type Raf kinase (BRAF) gene is a common genetic change in cases of papillary thyroid carcinoma (PTC) that appears to play a key... https://pubmed.ncbi.nlm.nih.gov/29209533/ Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II... Despite encouraging preclinical data, our study did not show signs of clinical activity for vinorelbine in this patients' population. Further investigations on... metastatic colorectal cancer https://www.wikidata.org/wiki/Q61350147 Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf... scientific article published on 07 September 2006 https://pubmed.ncbi.nlm.nih.gov/24353068/ Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of... Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case... https://research.rug.nl/en/publications/rraf-v600e-is-not-involved-in-the-colorectal-tumorigenesis-of-hnp/ RRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional... https://pubmed.ncbi.nlm.nih.gov/29271794/ BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and... The B-Raf proto-oncogene (BRAF) encodes a cytoplasmic serine/threonine kinase with a key role in regulating the mitogen-activated protein kinase signal... https://www.wikidata.org/wiki/Q39640222 PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive... scientific article published on December 2010 https://pubmed.ncbi.nlm.nih.gov/31672130/ Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E... Combined, our results support that inclusion of proteomics can predict drug response and identify co-therapies in a basket setting. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1468233/full Frontiers | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial... Thyroid metastasis of lung adenocarcinoma is exceedingly uncommon. Here we present a case of a 72-year-old Chinese male with hoarseness, dysphagia, pain, and...